Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
2.
Magnes Res ; 32(3): 63-71, 2019 Aug 01.
Article in English | MEDLINE | ID: mdl-32162607

ABSTRACT

BACKGROUND: Low magnesium (Mg) levels are linked to many diseases. Studies suggest that organic salts of Mg are more readily bioavailable than its oxide or inorganic salts used for supplements production. Unfortunately, the plethora of variables in the previous study designs complicates the making of any clear and reliable conclusions. METHODS: 14 healthy males were supplemented for five days with 400 mg Mg to saturate Mg pools before intake of the test products. Bioavailability of 400 mg Mg from Mg citrate (MgC) and Mg oxide (MgO) after single-dose administration was assessed by measuring renal Mg excretion in 24-h urine and blood plasma [Mg] at time points 0, 2, 4, 8, and 24 h. RESULTS: Single-dose MgC supplementation led to a significant (P < 0.05) increase in 24 h urinary Mg excretion, but this was not significant following MgO. Plasma [Mg] was also significantly higher for MgC than for MgO at 4 h (P < 0.05) and 8 h (P < 0.05). Compared with baseline levels, MgC supplementation showed a significant increase in plasma [Mg] at all time points, in contrast to MgO. CONCLUSIONS: MgC shows higher bioavailability compared with MgO. Furthermore, urinary Mg excretion should be determined as the primary endpoint of Mg bioavailability studies.


Subject(s)
Citric Acid/urine , Magnesium Oxide/urine , Magnesium/urine , Organometallic Compounds/urine , Adult , Biological Availability , Citric Acid/pharmacokinetics , Cross-Over Studies , Healthy Volunteers , Humans , Magnesium/administration & dosage , Magnesium/pharmacokinetics , Magnesium Oxide/pharmacokinetics , Male , Middle Aged , Organometallic Compounds/pharmacokinetics , Young Adult
3.
Clin Sci (Lond) ; 129(12): 1143-50, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26453619

ABSTRACT

Disturbed magnesium (Mg(2+)) homoeostasis and increased levels of OS (oxidative stress) are associated with poor clinical outcomes in patients suffering from neurodegenerative, cardiovascular and metabolic diseases. Data from clinical and animal studies suggest that MD (Mg(2+) deficiency) is correlated with increased production of ROS (reactive oxygen species) in cells, but a straightforward causal relationship (including molecular mechanisms) between the two conditions is lacking. The multifactorial protein PARK7/DJ-1 is a major antioxidant protein, playing a key role in cellular redox homoeostasis, and is a positive regulator of AR (androgen receptor)-dependent transcription. SLC41A1 (solute carrier family 41 member 1), the gene encoding a ubiquitous cellular Mg(2+)E (Mg(2+)efflux) system, has been shown to be regulated by activated AR. We hypothesize that overexpression/up-regulation of PARK7/DJ-1, attributable to OS and related activation of AR, is an important event regulating the expression of SLC41A1 and consequently, modulating the Mg(2+)E capacity. This would involve changes in the transcriptional activity of PARK7/DJ-1, AR and SLC41A1, which may serve as biomarkers of intracellular MD and may have clinical relevance. Imipramine, in use as an antidepressant, has been shown to reduce the Mg(2+)E activity of SLC41A1 and OS. We therefore hypothesize further that administration of imipramine or related drugs will be beneficial in MD- and OS-associated diseases, especially when combined with Mg(2+) supplementation. If proved true, the OS-responsive functional axis, PARK7/DJ-1-AR-SLC41A1, may be a putative mechanism underlying intracellular MD secondary to OS caused by pro-oxidative stimuli, including extracellular MD. Furthermore, it will advance our understanding of the link between OS and MD.


Subject(s)
Cardiovascular Diseases/etiology , Intracellular Signaling Peptides and Proteins/metabolism , Magnesium Deficiency/etiology , Metabolic Diseases/etiology , Neurodegenerative Diseases/etiology , Oncogene Proteins/metabolism , Oxidative Stress , Signal Transduction , Animals , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/prevention & control , Cation Transport Proteins/antagonists & inhibitors , Cation Transport Proteins/metabolism , Chronic Disease , Humans , Imipramine/therapeutic use , Magnesium Deficiency/drug therapy , Magnesium Deficiency/metabolism , Metabolic Diseases/metabolism , Metabolic Diseases/prevention & control , Molecular Targeted Therapy , Neurodegenerative Diseases/metabolism , Neurodegenerative Diseases/prevention & control , Oxidative Stress/drug effects , Protein Deglycase DJ-1 , Receptors, Androgen/metabolism , Risk Factors , Up-Regulation
4.
Arch Gynecol Obstet ; 288(6): 1269-74, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23715924

ABSTRACT

PURPOSE: To assess if hypertension during the last part of pregnancy could be prevented by magnesium supplementation. METHODS: Pregnant primagravida women from a local antenatal care unit were given an oral supply of 300 mg magnesium as citrate or placebo from pregnancy week 25 in a randomised double-blind setup. Blood pressure was recorded during pregnancy as well as pregnancy outcome. RESULTS: In the magnesium-supplemented group, the average diastolic blood pressure at week 37 was significantly lower than in the placebo group (72/1.4 mean/SEM vs 77/1.4, p = 0.031). The number of women with an increase in diastolic blood pressure of ≥15 mmHg was significantly lower in the magnesium group compared with the women who received placebo (p = 0.011). There was an inverse relation between the urinary excretion of magnesium during pregnancy and the diastolic blood pressure (p = 0.005). CONCLUSIONS: Magnesium supplementation prevented an increase in diastolic blood pressure during the last weeks of pregnancy. The relation between diastolic blood pressure and urinary excretion of magnesium suggests that magnesium is involved in the regulation of blood pressure and that the increase in diastolic blood pressure in pregnancy could be due to a lack of magnesium.


Subject(s)
Blood Pressure/drug effects , Citric Acid/administration & dosage , Hypertension/drug therapy , Organometallic Compounds/administration & dosage , Administration, Oral , Adult , Blood Pressure/physiology , Calcium/urine , Citric Acid/urine , Double-Blind Method , Female , Humans , Organometallic Compounds/urine , Pregnancy , Pregnancy Outcome , Pregnancy Trimester, Second , Pregnancy Trimester, Third , Socioeconomic Factors , Sweden , Treatment Outcome
5.
Metallomics ; 5(6): 745-52, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23686104

ABSTRACT

The highly conserved G-M-N motif of the CorA-Mrs2-Alr1 family of Mg(2+) channels has been shown to be essential for Mg(2+) transport. We performed random mutagenesis of the G-M-N sequence of Saccharomyces cerevisiae Mrs2p in an unbiased genetic screen. A large number of mutants still capable of Mg(2+) influx, albeit below the wild-type level, were generated. Growth complementation assays, performed in media supplemented with Ca(2+) or Co(2+) or Mn(2+) or Zn(2+) at varying concentrations, lead to identification of mutants with reduced growth in the presence of Mn(2+) and Zn(2+). We hereby conclude that (1) at least two, but predominantly all three amino acids of the G-M-N motif must be replaced by certain combinations of other amino acids to remain functional, (2) replacement of any single amino acid within the G-M-N motif always impairs the function of Mrs2p, and (3) we show that the G-M-N motif determines ion selectivity, likely in concurrence with the negatively charged loop at the entrance of the channel thereby forming the Mrs2p selectivity filter.


Subject(s)
Magnesium/metabolism , Saccharomyces cerevisiae Proteins/chemistry , Saccharomyces cerevisiae Proteins/metabolism , Saccharomyces cerevisiae/metabolism , Calcium/metabolism , Cobalt/metabolism , Manganese/metabolism , Substrate Specificity , Zinc/metabolism
6.
J Biol Chem ; 279(29): 30307-15, 2004 Jul 16.
Article in English | MEDLINE | ID: mdl-15138253

ABSTRACT

The yeast open reading frames YOL027 and YPR125 and their orthologs in various eukaryotes encode proteins with a single predicted trans-membrane domain ranging in molecular mass from 45 to 85 kDa. Hemizygous deletion of their human homolog LETM1 is likely to contribute to the Wolf-Hirschhorn syndrome phenotype. We show here that in yeast and human cells, these genes encode integral proteins of the inner mitochondrial membrane. Deletion of the yeast YOL027 gene (yol027Delta mutation) results in mitochondrial dysfunction. This mutant phenotype is complemented by the expression of the human LETM1 gene in yeast, indicating a functional conservation of LetM1/Yol027 proteins from yeast to man. Mutant yol027Delta mitochondria have increased cation contents, particularly K+ and low-membrane-potential Deltapsi. They are massively swollen in situ and refractory to potassium acetate-induced swelling in vitro, which is indicative of a defect in K+/H+ exchange activity. Thus, YOL027/LETM1 are the first genes shown to encode factors involved in both K+ homeostasis and organelle volume control.


Subject(s)
Calcium-Binding Proteins/metabolism , Membrane Proteins/metabolism , Mitochondria/metabolism , Multigene Family , Muscular Diseases/genetics , Potassium/metabolism , Saccharomyces cerevisiae Proteins/metabolism , Amino Acid Sequence , Animals , Calcium-Binding Proteins/genetics , Cloning, Molecular , DNA, Complementary/metabolism , Gene Deletion , Green Fluorescent Proteins , Homeostasis , Humans , Intracellular Membranes/metabolism , Luminescent Proteins/metabolism , Membrane Potentials , Membrane Proteins/genetics , Microscopy, Confocal , Microscopy, Electron , Microscopy, Fluorescence , Mitochondrial Proteins , Molecular Sequence Data , Mutation , Phenotype , Plasmids/metabolism , Potassium/chemistry , Potassium Acetate/pharmacology , Saccharomyces cerevisiae/metabolism , Saccharomyces cerevisiae Proteins/genetics , Sequence Homology, Amino Acid , Subcellular Fractions/metabolism , Syndrome , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL